Bulk Inquiry
Abiraterone acetate
- CB 7630 - JNJ 212082
- Optical Purity: Optically pure
- No solubility data
- MF: C26H33NO2
- MW: 391.55
Description
Orally administered prodrug of Abiraterone (Axon 1873); inhibitor of the steroidal enzyme 17 α-hydroxylase/C17,20 lyase (CYP17A1); a drug used in castration-resistant prostate cancer (CRPC)
More Information
| Parent CAS No. | 154229-18-2 |
|---|---|
| Chemical Name | (3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate |
| SMILES | [C@]12(C)CC[C@]3([H])[C@@]4(C)CC[C@H](OC(=O)C)CC4=CC[C@@]3([H])[C@]1([H])CC=C2C1C=NC=CC=1 |&1:0,4,6,10,19,21,r| |
| MFCD | N.A. |
| InChi | InChI=1S/C26H33NO2/c1-17(28)29-20-10-12-25(2)19(15-20)6-7-21-23-9-8-22(18-5-4-14-27-16-18)26(23,3)13-11-24(21)25/h4-6,8,14,16,20-21,23-24H,7,9-13,15H2,1-3H3/t20-,21-,23-,24-,25-,26+/m0/s1 |
| InChiKey | UVIQSJCZCSLXRZ-UBUQANBQSA-N |
| CID | 9821849 |
| Short Description | CYP17A1 inhibitor |
References
- G Attard et al. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int. 2005, 96 (9), 1241–1246.
- JE Ang et al. CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. Br. J. Cancer 2009, 100(5), 671–675.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1532 | RD 162 |
From $137.50 |
| 1557 | Posaconazole |
From $99.00 |
| 1564 | Tienilic Acid |
From $82.50 |
| 1595 | PPP hydrochloride |
From $104.50 |
| 1613 | MDV 3100 |
From $77.00 |
| 1680 | RU 58841 |
From $88.00 |
| 1873 | Abiraterone |
From $99.00 |
| 1979 | ARN 509 |
From $104.50 |
| 2026 | PF 04981517 |
From $165.00 |
| 2044 | Voriconazole |
From $93.50 |
| 2105 | Fluconazole |
From $66.00 |
| 2124 | TAK 700 |
From $115.50 |
| 2628 | TMS |
From $82.50 |
| 2922 | Sulfaphenazole |
From $66.00 |
| 3163 | Clotrimazole |
From $55.00 |
| 3190 | DLCI-1 |
From $88.00 |
